The firm will provide information on the seroprevalence of SARS-CoV-2, sharing results with demographic information and analysis in collaboration with the CDC.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
The population genomics firm said that it can provide 2,000 COVID-19 PCR tests per day out of its San Diego lab while it awaits FDA Emergency Use Authorization.